全文获取类型
收费全文 | 1003篇 |
免费 | 92篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 74篇 |
妇产科学 | 53篇 |
基础医学 | 91篇 |
口腔科学 | 36篇 |
临床医学 | 165篇 |
内科学 | 211篇 |
皮肤病学 | 27篇 |
神经病学 | 47篇 |
特种医学 | 156篇 |
外科学 | 73篇 |
综合类 | 27篇 |
预防医学 | 60篇 |
眼科学 | 12篇 |
药学 | 42篇 |
1篇 | |
中国医学 | 9篇 |
肿瘤学 | 51篇 |
出版年
2023年 | 2篇 |
2021年 | 8篇 |
2020年 | 8篇 |
2019年 | 6篇 |
2018年 | 21篇 |
2017年 | 23篇 |
2016年 | 24篇 |
2015年 | 29篇 |
2014年 | 40篇 |
2013年 | 41篇 |
2012年 | 18篇 |
2011年 | 27篇 |
2010年 | 42篇 |
2009年 | 67篇 |
2008年 | 29篇 |
2007年 | 47篇 |
2006年 | 23篇 |
2005年 | 25篇 |
2004年 | 12篇 |
2003年 | 13篇 |
2002年 | 11篇 |
2001年 | 22篇 |
2000年 | 14篇 |
1999年 | 25篇 |
1998年 | 70篇 |
1997年 | 81篇 |
1996年 | 57篇 |
1995年 | 52篇 |
1994年 | 37篇 |
1993年 | 43篇 |
1992年 | 14篇 |
1991年 | 9篇 |
1990年 | 12篇 |
1989年 | 26篇 |
1988年 | 22篇 |
1987年 | 27篇 |
1986年 | 14篇 |
1985年 | 17篇 |
1984年 | 11篇 |
1983年 | 12篇 |
1982年 | 10篇 |
1981年 | 8篇 |
1980年 | 9篇 |
1978年 | 5篇 |
1977年 | 11篇 |
1976年 | 5篇 |
1975年 | 2篇 |
1934年 | 1篇 |
1931年 | 1篇 |
1930年 | 1篇 |
排序方式: 共有1141条查询结果,搜索用时 15 毫秒
1.
Genetic and non‐genetic factors that increase the risk of non‐syndromic cleft lip and/or palate development 下载免费PDF全文
2.
Karen Feltmate Peter M. Janiszewski Sheena Gingerich Michael Cloutier 《Respirology (Carlton, Vic.)》2015,20(3):361-369
The development and commercialization of drugs for rare diseases, termed ‘orphan drugs’, has historically been economically unattractive. However, because of the introduction of legislation that provides financial and regulatory incentives for the development of orphan drugs, new developments are making their way through the regulatory approval processes. Unfortunately, delays in availability of new drugs for treating rare disease continue to persist. This paper reviews the approach of several regulatory jurisdictions to orphan drugs in an effort to determine their relative effectiveness in providing patient access. Generally speaking, regulatory authorities across jurisdictions have recognized the need to enhance timely access to safe, effective treatment for patients with rare diseases and have been able to shift the approval timelines for access to new care. The greater impediment to orphan drug access appears to be funding, particularly in publicly sponsored health‐care systems. Redundancies in federal and provincial reviews of orphan drugs can result in significant delays in access to new drugs. Clearly, more must be done to accelerate access to the treatments so desperately needed by patients. Public payers must be held accountable for their process and decisions—especially for rare disease therapies. 相似文献
3.
4.
The midwifery art has emphasised the uniqueness of human beings throughout its Nordic history. The educated Nordic midwife has in the last decade celebrated several hundred years of memories. This article studies how the key ideas of the midwifery art and patterns of ideas become evident in the zeitgeist from the beginning of the 19th century to the millennium in the Nordic countries. The legacy and pattern of ideas of the art of midwifery are interpreted in relation to the texts of the selected historical sources and based on Ricoeur's phenomenological-hermeneutic approach to the text and further to the dedication of understanding and interpretation. The historical sources refer to unprinted primary sources from historical archives and printed secondary and tertiary sources. The patterns of ideas include a tripartite whole: the true cultivation of the head, the philosophy and aesthetics of the hand, the strength of the heart and the drive of calling. These ideas open for unique visions and attest to the evident in modern midwives. Today's midwives have academic training with examinations, and the education is based on scientific evidence. The midwife profession is authorised by the state and supervised by the authorities. 相似文献
5.
6.
7.
ObjectiveThis meta-evaluation aimed to summarize all available evidence regarding different fissure sealants on occlusal caries prevention, arrest, retention rate, adverse effect, and cost-effectiveness; when compared with no intervention, other preventive or minimally-invasive procedures.Materials and MethodsThe systematic reviews and meta-analyses were identified via four electronic databases and manual searching. Two independent reviewers performed study selection, data extraction, quality assessment with AMSTAR-2.ResultsAmong the 366 records yielded, 38 systematic reviews were identified as eligible 24 of them included meta-analyses. Moderate evidence has supported the efficacies of resin-based sealants (RBS) in occlusal caries prevention, arrest and cost-effectiveness compared to no interventions. Low to very low certainty of evidence suggested similar effectiveness of glass-ionomer cements in caries prevention with RBS and more superior performance of resin infiltration in arresting non-cavitated occlusal lesions.ConclusionThis meta-evaluation supports the use of RBS on permanent molars to reduce occlusal caries occurrence, arrest lesion progression and alleviate oral health inequalities between individuals of different socioeconomic status. This meta-evaluation also advocates further research on glass-ionomer cements and resin infiltration with respect to their efficacies in caries prevention and arrest. 相似文献
8.
Decision aids for localized prostate cancer treatment choice: Systematic review and meta‐analysis 下载免费PDF全文
Philippe D. Violette MD CM Thomas Agoritsas MD Paul Alexander MSc MHSc Jarno Riikonen MD PhD Henrikki Santti MD PhD Arnav Agarwal BHSc Neera Bhatnagar MLIS Philipp Dahm MD MHSc Victor Montori MD MSc Gordon H. Guyatt MD MSc Kari A. O. Tikkinen MD PhD 《CA: a cancer journal for clinicians》2015,65(3):239-251
Patients who are diagnosed with localized prostate cancer need to make critical treatment decisions that are sensitive to their values and preferences. The role of decision aids in facilitating these decisions is unknown. The authors conducted a systematic review of randomized trials of decision aids for localized prostate cancer. Teams of 2 reviewers independently identified, selected, and abstracted data from 14 eligible trials (n = 3377 men), of which 10 were conducted in North America. Of these, 11 trials compared decision aids with usual care, and 3 trials compared decision aids with other decision aids. Two trials suggested a modest positive impact on decisional regret. Results across studies varied widely for decisional conflict (4 studies), satisfaction with decision (2 studies), and knowledge (2 studies). No impact on treatment choices was observed (6 studies). In conclusion, scant evidence at high risk of bias suggests the variable impact of existing decision aids on a limited set of decisional processes and outcomes. Because current decision aids provide information but do not directly facilitate shared decision making, subsequent efforts would benefit from user‐centered design of decision aids that promote shared decision making. CA Cancer J Clin 2015;65: 239–251. © 2015 American Cancer Society. 相似文献
9.
James R. Conner Emily Meserve Ellen Pizer Judy Garber Michael Roh Nicole Urban Charles Drescher Bradley J. Quade Michael Muto Brooke E. Howitt Mark D. Pearlman Ross S. Berkowitz Neil Horowitz Christopher P. Crum Colleen Feltmate 《Gynecologic oncology》2014
Objective
This study computed the risk of clinically silent adnexal neoplasia in women with germ-line BRCA1 or BRCA2 mutations (BRCAm +) and determined recurrence risk.Methods
We analyzed risk reduction salpingo-oophorectomies (RRSOs) from 349 BRCAm + women processed by the SEE-FIM protocol and addressed recurrence rates for 29 neoplasms from three institutions.Results
Nineteen neoplasms (5.4%) were identified at one institution, 9.2% of BRCA1 and 3.4% of BRCA2 mutation-positive women. Fourteen had a high-grade tubal intraepithelial neoplasm (HGTIN, 74%). Mean age (54.4) was higher than the BRCAm + cohort without neoplasia (47.8) and frequency increased with age (p < 0.001). Twenty-nine BRCAm + patients with neoplasia from three institutions were followed for a median of 5 years (1–8 years.). One of 11 with HGTIN alone (9%) recurred at 4 years, in contrast to 3 of 18 with invasion or involvement of other sites (16.7%). All but two are currently alive. Among the 29 patients in the three institution cohort, mean ages for HGTIN and advanced disease were 49.2 and 57.7 (p = 0.027).Conclusions
Adnexal neoplasia is present in 5–6% of RRSOs, is more common in women with BRCA1 mutations, and recurs in 9% of women with HGTIN alone. The lag in time from diagnosis of the HGTIN to pelvic recurrence (4 years) and differences in mean age between HGTIN and advanced disease (8.5 years) suggest an interval of several years from the onset of HGTIN until pelvic cancer develops. However, some neoplasms occur in the absence of HGTIN. 相似文献10.
Marcella C Müller Joost CM Meijers Margreeth B Vroom Nicole P Juffermans 《Critical care (London, England)》2014,18(1)